| Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi |
NCT03603509: Gene Signatures of Influenza Vaccine Responses in Older Adults |
|
|
| Completed | 4 | 241 | US | Fluad Vaccine, adjuvanted influenza vaccine, Fluzone High-Dose, high dose influenza vaccine | Mayo Clinic, National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 01/19 | 01/19 | | |
| Completed | 4 | 267 | US | FLUAD® Quadrivalent, Influenza Vaccine, Adjuvanted (Quadrivalent), aIIV4, Fluzone® High-Dose Quadrivalent, High-Dose Quadrivalent Influenza Vaccine, HD-IIV4, SHINGRIX®, Zoster Vaccine Recombinant, Adjuvanted (RZV) | Duke University, Centers for Disease Control and Prevention, Johns Hopkins University | Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event | 03/23 | 06/23 | | |
NCT04080531: Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders |
|
|
| Completed | 4 | 165 | US | Pneumococcal 13-valent Conjugate Vaccine, PCV13, Prevnar 13, Trivalent Influenza Vaccine, Flu shot, Flu vaccination, Fluzone, Fluzone HD, Fluzone High-dose, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV | Emory University, Sanofi, National Institutes of Health (NIH), National Cancer Institute (NCI) | Plasma Cell Neoplasm | 05/21 | 12/22 | | |
NCT04101838: B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults |
|
|
| Recruiting | 4 | 50 | US | Fluzone, influenza vaccine, Flucelvax, Fluzone High-Dose, high dose influenza vaccine, Fluad, adjuvanted influenza vaccine | University of Alabama at Birmingham | Influenza | 05/24 | 05/25 | | |
DANFLU-2, NCT05517174: A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults |
|
|
| Recruiting | 4 | 286900 | Europe | High-Dose Quadrivalent Influenza Vaccine, QIV-HD, Standard-Dose Quadrivalent Influenza Vaccine, QIV-SD | Tor Biering-Sørensen, Sanofi, Statens Serum Institut | Influenza | 05/25 | 08/25 | | |
| Recruiting | 4 | 400 | US | Standard dose influenza vaccination, Fluzone quadrivalent, High dose influenza vaccination, Fluzone high dose quadrivalent | University of Miami | Human Influenza | 09/25 | 09/25 | | |
PIVOT, NCT03330132: Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong |
|
|
| Active, not recruiting | 4 | 1861 | RoW | Standard inactivated influenza vaccine (NH formulation), MF 59 adjuvanted inactivated influenza vaccine (NH formulation), High-dose inactivated influenza vaccine (NH formulation), Recombinant hemagglutinin inactivated influenza vaccine (NH formulation) | The University of Hong Kong, Centers for Disease Control and Prevention | Influenza, Human | 12/25 | 12/26 | | |
| Recruiting | 4 | 66 | US | Flu Vaccine (Year 1), Fluzone® Quadrivalent High-Dose, Flu Vaccine (Year 2), FLUAD, Flu Vaccine (Year 3) | The Jackson Laboratory, UConn Health, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID) | Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response | 12/26 | 12/26 | | |
2021-003953-43: COVID-19: A Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older |
|
|
| Ongoing | 3 | 1680 | Europe | Ad26.COV2.S, Afluria Quadrivalent, Fluzone High-Dose Quadrivalent, VAC31518, Suspension for injection, Suspension for injection in pre-filled syringe, Afluria Quadrivalent, Fluzone High-Dose Quadrivalent | Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V., Biomedical Advanced Research and Development Authority (BARDA) | Healthy Volunteers (Prevention of COVID-19 and influenza), Healthy Volunteers (Prevention of COVID-19 and influenza), Diseases [C] - Virus Diseases [C02] | | | | |
2019-001401-25: Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older |
|
|
| Not yet recruiting | 3 | 121000 | Europe | quadrivalent influenza vaccine high dose, VaxigripTetra, J07BB, Suspension for injection in pre-filled syringe, Efluelda, VaxigripTetra | Sanofi Pasteur Inc., Sanofi Pasteur | Prevention of influenza infection in adults from 65 years of age and older, Active immunisation of adults from 65 years of age and older againstinfluenza infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients |
|
|
| Recruiting | 3 | 4000 | RoW | Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP | The University of Hong Kong | Influenza | 09/22 | 03/23 | | |
NCT06060457: A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age |
|
|
| Completed | 3 | 1900 | US | Placebo, mRNA-1345, Fluzone HD | ModernaTX, Inc. | Respiratory Syncytial Virus | 06/24 | 06/24 | | |
2019-001974-27: Reducing the Burden of Influenza after Solid-Organ Transplantation: the STOP-FLU trial Reducción de la carga de enfermedad por gripe tras un trasplante de órganos sólidos: ensayo clínico STOP-FLU |
|
|
| Not yet recruiting | 2/3 | 780 | Europe | Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, VaxigripTetra®, Fluad®, Fluzone High Dose® | Centre Hospitalier Universitaire Vaudois (CHUV), Swiss National Science Foundation | Influenza in solid organ transplant patients Gripe en pacientes con trasplante de órgano sólido, Influenza in solid organ transplant patients Gripe en pacientes con trasplante de órgano sólido, Diseases [C] - Virus Diseases [C02] | | | | |
2021-003170-31: Feasibility of Conducting a Study Comparing High-Dose Influenza Vaccines to Standard-Dose Influenza Vaccines in Danish Citizens Aged 65-79 Years |
|
|
| Not yet recruiting | 2 | 40000 | Europe | High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine, Suspension for injection in pre-filled syringe, Efluelda®, Standard-Dose Quadrivalent Influenza Vaccine | Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital, Sanofi Pasteur | Prevention of influenza infection in adults aged 65-79 years, Active immunisation of adults aged 65-79 years againstinfluenza infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04613206: High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients |
|
|
| Recruiting | 2 | 396 | US | High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone | Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, University of Washington | Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant | 12/24 | 04/25 | | |
NCT05291676: Systems Investigation of Vaccine Responses in Aging and Frailty |
|
|
| Recruiting | 2 | 96 | US | Fluzone, Fluad | Yale University, National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | | | | |
NCT05215327: High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients |
|
|
| Recruiting | 2 | 270 | US | High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose, Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone | Vanderbilt University Medical Center, Northwestern University Feinberg School of Medicine, University of Alabama at Birmingham, University of Washington, Duke University | Immunization; Infection, Transplantation Infection, Influenza | 07/27 | 12/27 | | |
PSOT, NCT05947071: High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients |
|
|
| Not yet recruiting | 2 | 312 | US | Standard Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone, High Dose Quadrivalent Inactivated Influenza Vaccine, Fluzone High Dose | National Institute of Allergy and Infectious Diseases (NIAID), Children's Hospital Medical Center, Cincinnati, Lucile Packard Children's Hospital, University of Pittsburgh, Ann & Robert H Lurie Children's Hospital of Chicago, Baylor College of Medicine, Children's Mercy Hospital Kansas City, Children's Healthcare of Atlanta | Immunization; Infection, Transplantation Infection, Influenza | 07/27 | 09/27 | | |
NCT05553301: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older |
|
|
| Completed | 1/2 | 560 | US | Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Flublok Quadrivalent®, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza High-Dose Vaccine, Fluzone High-Dose Quadrivalent® | Sanofi Pasteur, a Sanofi Company | Influenza Immunization | 01/24 | 01/24 | | |
NCT05650554: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older |
|
|
| Completed | 1/2 | 682 | US, RoW | Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Flublok Quadrivalent®, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza High-Dose Vaccine, Fluzone High-Dose Quadrivalent® | Sanofi Pasteur, a Sanofi Company | Influenza Immunization | 04/24 | 04/24 | | |
NCT05624606: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older |
|
|
| Completed | 1/2 | 682 | US | Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Flublok Quadrivalent®, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Fluzone Quadrivalent®, Quadrivalent Inactivated Influenza High Dose QIV-HD, Fluzone High-Dose Quadrivalent® | Sanofi Pasteur, a Sanofi Company | Influenza Immunization | 03/24 | 03/24 | | |
NCT06361875: A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above |
|
|
| Active, not recruiting | 1/2 | 1002 | US, RoW | Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Fluzone Qudrivalent®, Quadrivalent Influenza High-Dose Vaccine, Fluzone High-Dose Quadrivalent®, Quadrivalent Recombinant Influenza Vaccine, Flublok Quadrivalent® | Sanofi Pasteur, a Sanofi Company | Influenza Immunization | 05/25 | 05/25 | | |
SLVP033, NCT03312699: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort |
|
|
| Completed | 1 | 54 | US | Fluzone® quadrivalent, IIV4 inactivated influenza vaccine, Fluzone High Dose, High Dose Trivalent, inactivated influenza vaccine (TIV), Fluad, Adjuvanted Trivalent, inactivated influenza vaccine, Vaqta, Inactivated Hepatitis A Vaccine, Typhim Vi, Typhoid Vi Polysaccharide Vaccine, Vivotif, Typhoid Vaccine Live Oral Ty21a | Stanford University, National Institute of Allergy and Infectious Diseases (NIAID) | Influenza, Hepatitis A, Typhoid, Healthy Adults | 12/23 | 12/23 | | |
NCT05426174: Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older |
|
|
| Completed | 1 | 233 | US | mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine, Fluzone HD | Sanofi Pasteur, a Sanofi Company | Influenza Immunization, Healthy Volunteers | 01/24 | 01/24 | | |
NCT06229392: A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer |
|
|
| Recruiting | 1 | 18 | US | Fluzone Quadrivalent | Rush University Medical Center | Breast Cancer, Breast Cancer Triple Negative | 12/25 | 12/25 | | |
NCT06059456: Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24 |
|
|
| Completed | N/A | 2075 | Europe | Quadrivalent Influenza Vaccine, VaxigripTetra®, High-Dose Quadrivalent Influenza Vaccine, Efluelda® | Sanofi | Influenza Immunization (Healthy Volunteers) | 12/23 | 12/23 | | |
CHRONOVAX, NCT06088563: Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX |
|
|
| Recruiting | N/A | 100 | Europe | Vaccine injection, EFLUELDA - Fluzone High-Dose Quadrivalent | Centre Hospitalier Universitaire de Nice | Vaccination; Infection | 10/24 | 10/24 | | |
NCT06029933: Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years |
|
|
| Recruiting | N/A | 960000 | US | Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), Fluad, High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4), Fluzone High-Dose | Kaiser Permanente, Seqirus | Influenza, Community-acquired Pneumonia, Cardiovascular Events | 05/25 | 05/26 | | |
NCT05663463: Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients |
|
|
| Recruiting | N/A | 100 | US | Fluzone High-Dose Quadrivalent- 2 doses, Fluzone High-Dose Quadrivalent- 1 dose of HD | University of Minnesota | Solid Organ Transplant | 09/25 | 12/25 | | |
